NCT01156870View on ClinicalTrials.gov

First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

September 8, 2010

Primary Completion Date

April 7, 2017

Study Completion Date

April 7, 2017

Conditions
Neoplasm Malignant
Interventions
DRUG

SAR566658

"Pharmaceutical form:solution for infusion~Route of administration: intravenous"

Trial Locations (5)

28040

Investigational Site Number 724002, Madrid

28050

Investigational Site Number 724001, Madrid

31052

Investigational Site Number 250001, Toulouse

78229

Investigational Site Number 840001, San Antonio

45267-0542

Investigational Site Number 840002, Cincinnati

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY